PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Meurin, Philippe
TI  - POPE-2: No Benefit with Colchicine to Reduce Persistent Postoperative Pericardial Effusion
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 15--15
VI  - 14
IP  - 27
4099  - http://mdc.sagepub.com/content/14/27/15.1.short
4100  - http://mdc.sagepub.com/content/14/27/15.1.full
AB  - Postoperative pericardial effusion (POPE) is present within the first 7 days after cardiac surgery in 50% to 80% of patients, and the risk for early cardiac tamponade ranges from 0.5% to 1%. There is no drug that can treat this local hemorrhagic complication. The Colchicine Treatment for Post-operative Pericardial Effusion [POPE-2; NCT01266694] was a double-blind, placebo-controlled study to evaluate whether COL could reduce the volume of POPE.